A 26-Week, Multi-Center, Open-label, Randomized, Parallel-group Study to Evaluate the Efficacy and Safety of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-Term Intensive Insulin Therapy: Basal Insulin Based Treatment (With Prandial OADs Combination) Versus Twice-daily Premixed Insulin
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Insulin glargine (Primary) ; Insulin glulisine (Primary) ; Acarbose; Insulin aspart; Metformin; Repaglinide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms BEYOND V; SWITCH
- Sponsors Sanofi
- 06 Aug 2020 Status changed from active, no longer recruiting to completed.
- 04 Mar 2020 Trial design published in the Advances in Therapy
- 07 Jan 2020 Planned End Date changed from 1 Feb 2021 to 1 May 2020.